CClinicalTrials.gg
TerminatedNCT03953690e-LUPUSUpdated Oct 2, 2023

Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a Specialised Centre in France

An observational study in Lupus, sponsored by Centre Hospitalier Universitaire Dijon. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-02.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

Why this study was terminated
lack of support from doctors and patients
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
221
Ages
18 Years and older
Sex
All
01

Study summary

Systemic lupus erythematosus (SLE) is a complex disease whose evaluation in daily practice and clinical research requires consideration of several aspects, in particular disease activity and quality of life.

Health systems are increasingly using Patient Reported Outcome measures (PRO) data to measure different dimensions of the disease and its experience.

In addition, there is a growing number of "e-health" tools for patients. Indeed, the collection of health-related data via an electronic system makes it possible to modernise and facilitate communication between patients and doctors within the framework of medical follow-up and therapeutic education. Nevertheless, very few studies measure the acceptability and effective long-term use of such tools, particularly in the context of SLE.

The Sanoïa patient platform is a digital tool already used in therapeutic areas similar to SLE (discoid lupus erythematosus and rheumatoid arthritis), offering a guarantee of safety and a reduced individual cost.

The availability of this health-related quality of life data collection tool via a site and a mobile application adapted to patients with SLE should:

  • Facilitate the collection by patients of their quality of life as part of their routine follow-up (patient access)
  • Limit the impact of patients' clinical profiles on the frequency of the collection of quality of life data
  • Enable internal medicine specialists to systematically use their patients' quality of life data during consultation (physician access).

This study therefore proposes to evaluate this digital platform within the framework of SLE by measuring the distribution of access by physicians according to the data reported by patients and according to the characteristics of the facilities where the subjects were recruited for the study. These data will allow us to evaluate the influence of factors extrinsic to patients on the adoption of the tool. This area has been very poorly evaluated in the few studies that have focused on the adoption of such tools.

02

Conditions studied

  • Lupus
03

In context

Lead sponsor

Centre Hospitalier Universitaire Dijon is the lead sponsor of 495 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients attending a consultation in their usual treatment centre

Inclusion criteria

  • Adult > 18 years old
  • Having given oral consent for participation
  • Confirmed systemic lupus diagnosis (ACR criteria)
  • Regular follow-up in the centre for more than 12 months
  • With Internet access at home
  • Affiliated with national health insurance system or other system

Exclusion criteria

Exclusion Criteria:

  • Persons subject to a legal protection measure (curatorship, guardianship)
  • Persons subject to limited judicial protection
  • Adults who are incapable or unable to express their consent
  • Patients who cannot read French
  • Patients whose cognitive status does not allow them to track their health data on a digital platform
  • Patients to be followed up in another centre within 12 months
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
221 participants (actual)
Patient registry
No

Interventions

  • Otheruse of e-Health service

    use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation

06

What researchers measure

Primary outcomes

  1. utilization rate of online patient account

    rate of use of the patient account at least twice, at least 1 month apart, over a 12-month period

    Time frame: Through study completion, an average of 24 months

07

Study locations

1 site
  • Centre Hospitalier Universitaire
    Dijon, 21079, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03953690
Lead sponsor
Centre Hospitalier Universitaire Dijon
Responsible party
Sponsor
First posted
May 16, 2019
Start date
Mar 19, 2020
Primary completion
Dec 5, 2022
Completion
Dec 5, 2022
Last update
Oct 2, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion